U.S. Markets close in 5 hrs 11 mins

Allergy Therapeutics plc (AGY.L)


LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
24.50-0.75 (-2.97%)
As of 5:09PM BST. Market open.
People also watch
APH.LVEC.LVER.LAMS.LABC.L

Allergy Therapeutics plc

Dominion Way
Worthing BN14 8SA
United Kingdom
44 19 0384 4700
http://www.allergytherapeutics.com

SectorHealthcare
IndustryDrug Manufacturers - Major
Full Time Employees440

Key Executives

NameTitlePayExercisedAge
Mr. Manuel LlobetChief Exec. Officer and Exec. Director407.96kN/A53
Mr. Nicolas Alexander Ulrich WykemanFin. Director and Exec. DirectorN/AN/A52
Ms. Beverly LeesOperations DirectorN/AN/AN/A
Dr. Murray SkinnerChief Scientific OfficerN/AN/AN/A
Mr. Santiago PuigBus. Devel. DirectorN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Allergy Therapeutics plc, a specialty pharmaceutical company, focusing on allergy vaccination primarily in Europe. The company’s primary flagship products consist of the Pollinex Quattro for the treatment of allergic conditions; and monophosphoryl-lipid A, a substance that enhances the immune response to an antigen or allergen. It offers sublingual product, including Oralvac Compact; Venomil product, which is used for the wasp and bee treatment; probiotic products, such as Kallergen-Th, ATI Prob, and Pollagen; Acarovac Plus, a novel tyrosine-adsorbed, modified-allergen product developed for treatment of perennial mite allergy; and DAP, a product for use in the diagnosis of type I or immediate hypersensitivity to benzyl penicillin and related antibiotics (beta lactams) by means of cutaneous tests (prick and intradermal). It is also developing products based on synbiotics that are special formulations of prebiotics and probiotics, such as Kallergen Th and SynGut; Polyvac, a peanut VLP adjuvanted specific immunotherapy; Acarovac Plus and Acarovac MPL that are next generation products for dust mite immunotherapy; and G102, G204, G205, and G306, as well as PQBirch 301 and PQBirch 204 that are subcutaneous immunotherapies, which are in various development phases. The company markets its products in injectable and sublingual formats under various brands. Allergy Therapeutics plc was founded in 1934 and is based in Worthing, the United Kingdom.

Corporate Governance

Allergy Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.